1. Academic Validation
  2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  • Nature. 2005 Apr 14;434(7035):917-21. doi: 10.1038/nature03445.
Hannah Farmer 1 Nuala McCabe Christopher J Lord Andrew N J Tutt Damian A Johnson Tobias B Richardson Manuela Santarosa Krystyna J Dillon Ian Hickson Charlotte Knights Niall M B Martin Stephen P Jackson Graeme C M Smith Alan Ashworth
Affiliations

Affiliation

  • 1 Cancer Research UK Gene Function and Regulation Group, London, UK.
Abstract

BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers. Poly(ADP-ribose) polymerase (PARP) is an Enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks. We show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent Apoptosis. This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination. These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for Cancer.

Figures
Products